Читать книгу The SAGE Encyclopedia of Stem Cell Research - Группа авторов - Страница 243

Angiogenesis, which is spread of a tumor via growth of new blood vessels, is considered to be an important target for cancer therapy. However, there is no data that incorporation of angiogenesis inhibitors has an impact on overall survival for women with triple-negative breast cancer. Therefore, this treatment has not yet been implied in breast cancer patients. Of agents in this class, bevacizumab has been the most widely studied. Unfortunately, incorporation of bevacizumab has virtually no impact on overall survival. This appears to be true even for patients with triple-negative breast cancer when bevacizumab was administered in the adjuvant and first-line metastatic settings.